{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:18:04Z","timestamp":1791901084757,"version":"4.3.4"},"reference-count":147,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["A14"],"award-info":[{"award-number":["A14"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["125440785 \\u2013 SFB 877"],"award-info":[{"award-number":["125440785 \\u2013 SFB 877"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 877"],"award-info":[{"award-number":["SFB 877"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.bbamcr.2021.119143","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T07:24:36Z","timestamp":1633591476000},"page":"119143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease"],"prefix":"10.1016","volume":"1869","author":[{"given":"Tim","family":"Schumertl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Lokau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rose-John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Garbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cytogfr.2012.04.001","article-title":"Plasticity and cross-talk of interleukin 6-type cytokines","volume":"23","author":"Garbers","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1\u20132","key":"10.1016\/j.bbamcr.2021.119143_bb0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1432-1033.1992.tb19838.x","article-title":"Glycosylation of interleukin-6 purified from normal human blood mononuclear cells","volume":"203","author":"Parekh","year":"1992","journal-title":"Eur. J. Biochem. FEBS"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119143_bb0015","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1084\/jem.20031205","article-title":"N-linked glycosylation is required for optimal function of Kaposi\u2019s sarcoma herpesvirus-encoded, but not cellular, interleukin 6","volume":"199","author":"Dela Cruz","year":"2004","journal-title":"J. Exp. Med."},{"issue":"24","key":"10.1016\/j.bbamcr.2021.119143_bb0020","doi-asserted-by":"crossref","first-page":"13380","DOI":"10.1002\/anie.202101496","article-title":"Natural glycoforms of human interleukin 6 show atypical plasma clearance","volume":"60","author":"Reif","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"21","key":"10.1016\/j.bbamcr.2021.119143_bb0025","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1074\/jbc.M113.466169","article-title":"Minimal interleukin (IL-)6 receptor stalk composition for IL-6R shedding and IL-6 classic signaling","volume":"288","author":"Baran","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2021.119143_bb0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.biochi.2015.11.005","article-title":"Modular organization of interleukin-6 and interleukin-11 \u03b1-receptors","volume":"119","author":"Nitz","year":"2015","journal-title":"Biochimie"},{"issue":"5628","key":"10.1016\/j.bbamcr.2021.119143_bb0035","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1126\/science.1083901","article-title":"Hexameric structure and assembly of the interleukin-6\/IL-6 alpha-receptor\/gp130 complex","volume":"300","author":"Boulanger","year":"2003","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119143_bb0040","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nsmb941","article-title":"Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor","volume":"12","author":"Skiniotis","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"Pt 20","key":"10.1016\/j.bbamcr.2021.119143_bb0045","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1242\/jcs.113.20.3593","article-title":"The cytoplasmic domain of the interleukin-6 receptor gp80 mediates its basolateral sorting in polarized Madin-Darby canine kidney cells","volume":"113","author":"Martens","year":"2000","journal-title":"J. Cell Sci."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119143_bb0050","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.celrep.2016.06.062","article-title":"Transcytosis of IL-11 and apical redirection of gp130 is mediated by IL-11alpha receptor","volume":"16","author":"Monhasery","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbamcr.2021.119143_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100434","article-title":"Interleukin-6 controls recycling and degradation, but not internalization of its receptors","volume":"296","author":"Flynn","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bbamcr.2021.119143_bb0060","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.4049\/jimmunol.1701191","article-title":"Granulocytes are unresponsive to IL-6 due to an absence of gp130","volume":"200","author":"Wilkinson","year":"2018","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0065","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0092-8674(89)90438-8","article-title":"Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130","volume":"58","author":"Taga","year":"1989","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119143_bb0070","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","article-title":"Molecular cloning and expression of an IL-6 signal transducer, gp130","volume":"63","author":"Hibi","year":"1990","journal-title":"Cell"},{"issue":"5143","key":"10.1016\/j.bbamcr.2021.119143_bb0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1126\/science.8272873","article-title":"Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components","volume":"263","author":"Stahl","year":"1994","journal-title":"Science"},{"issue":"5202","key":"10.1016\/j.bbamcr.2021.119143_bb0080","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.7871433","article-title":"Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors","volume":"267","author":"Stahl","year":"1995","journal-title":"Science"},{"issue":"6636","key":"10.1016\/j.bbamcr.2021.119143_bb0085","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/43206","article-title":"A family of cytokine-inducible inhibitors of signalling","volume":"387","author":"Starr","year":"1997","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119143_bb0090","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119143_bb0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbamcr.2021.119143_bb0100","first-page":"1","article-title":"Interleukins in cancer: from biology to therapy","volume":"3","author":"Briukhovetska","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbamcr.2021.119143_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-021-00473-x","article-title":"New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology","author":"Giraldez","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6\u20137","key":"10.1016\/j.bbamcr.2021.119143_bb0110","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ejcb.2011.09.010","article-title":"Interleukin-6 signalling: more than Jaks and STATs","volume":"91","author":"Eulenfeld","year":"2012","journal-title":"Eur. J. Cell Biol."},{"issue":"7541","key":"10.1016\/j.bbamcr.2021.119143_bb0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14228","article-title":"A gp130-Src-YAP module links inflammation to epithelial regeneration","volume":"519","author":"Taniguchi","year":"2015","journal-title":"Nature"},{"issue":"Pt 2","key":"10.1016\/j.bbamcr.2021.119143_bb0120","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3000281","article-title":"Soluble receptors for cytokines and growth factors: generation and biological function","volume":"300","author":"Rose-John","year":"1994","journal-title":"Biochem. J."},{"issue":"7","key":"10.1016\/j.bbamcr.2021.119143_bb0125","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1091\/mbc.e05-12-1129","article-title":"Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells","volume":"17","author":"Stuhlmann-Laeisz","year":"2006","journal-title":"Mol. Biol. Cell"},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbamcr.2021.119143_bb0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cytogfr.2020.04.003","article-title":"Biological functions and therapeutic opportunities of soluble cytokine receptors","volume":"55","author":"Lokau","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"9","key":"10.1016\/j.bbamcr.2021.119143_bb0140","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.bbadis.2014.05.018","article-title":"The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases","volume":"1842","author":"Garbers","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/1043-4666(92)90043-Q","article-title":"Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor","volume":"4","author":"Lust","year":"1992","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.bbamcr.2021.119143_bb0150","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/eji.1830240837","article-title":"Soluble interleukin-6 receptors released from T cell or granulocyte\/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism","volume":"24","author":"Horiuchi","year":"1994","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0155","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1432-1033.1996.00837.x","article-title":"Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing","volume":"236","author":"M\u00fcller-Newen","year":"1996","journal-title":"Eur. J. Biochem."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119143_bb0160","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.4049\/jimmunol.149.6.2021","article-title":"Complex of soluble human IL-6-receptor\/IL-6 up-regulates expression of acute-phase proteins","volume":"149","author":"Mackiewicz","year":"1992","journal-title":"J. Immunol."},{"issue":"43","key":"10.1016\/j.bbamcr.2021.119143_bb0165","doi-asserted-by":"crossref","first-page":"26059","DOI":"10.1074\/jbc.M115.649509","article-title":"Shedding of endogenous interleukin-6 receptor (IL-6R) is governed by a disintegrin and metalloproteinase (ADAM) proteases while a full-length IL-6R isoform localizes to circulating microvesicles","volume":"290","author":"Schumacher","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119143_bb0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1006\/cyto.1996.0055","article-title":"A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA","volume":"8","author":"Oh","year":"1996","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119143_bb0175","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1002\/(SICI)1521-4141(199811)28:11<3514::AID-IMMU3514>3.0.CO;2-T","article-title":"Shedding of the soluble IL-6 receptor is triggered by Ca2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells","volume":"28","author":"Jones","year":"1998","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0180","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1046\/j.1365-2567.1998.00622.x","article-title":"High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia\/HTLV-I-associated myelopathy","volume":"95","author":"Horiuchi","year":"1998","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119143_bb0185","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1043-4666(98)90003-5","article-title":"Acute myeloblastic leukaemia cells produce soluble interleukin 6 receptor by a mechanism of alternative splicing","volume":"10","author":"S\u00e4ily","year":"1998","journal-title":"Cytokine"},{"issue":"10","key":"10.1016\/j.bbamcr.2021.119143_bb0190","first-page":"2693","article-title":"Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage","volume":"5","author":"Thabard","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0195","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2011-07-367052","article-title":"An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification","volume":"119","author":"Stephens","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0200","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.cyto.2012.12.025","article-title":"Alternative splicing and proteolytic rupture contribute to the generation of soluble IL-6 receptors (sIL-6R) in rheumatoid arthritis","volume":"61","author":"Lamas","year":"2013","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119143_bb0205","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.4049\/jimmunol.159.11.5648","article-title":"Oncostatin M stimulates the expression and release of the IL-6 receptor in human hepatoma HepG2 cells","volume":"159","author":"Cichy","year":"1997","journal-title":"J. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.bbamcr.2021.119143_bb0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0165-2478(02)00022-6","article-title":"Soluble interleukin-6 receptor enhanced by oncostatin M induces major changes in gene expression profile of human hepatoma cells","volume":"82","author":"Holub","year":"2002","journal-title":"Immunol. Lett."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0215","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0165-2478(99)00040-1","article-title":"truncated\u2019 interleukin-6 receptor (IL-6R) mRNA by alternative splicing; a possible source of soluble IL-6R","volume":"68","author":"Holub","year":"1999","journal-title":"Immunol. Lett."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119143_bb0220","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s12192-010-0192-z","article-title":"The response of interleukin-6 and soluble interleukin-6 receptor isoforms following intermittent high intensity and continuous moderate intensity cycling","volume":"15","author":"Leggate","year":"2010","journal-title":"Cell Stress Chaperones"},{"issue":"12","key":"10.1016\/j.bbamcr.2021.119143_bb0225","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1096\/fj.06-5754fje","article-title":"Sleep enhances IL-6 trans-signaling in humans","volume":"20","author":"Dimitrov","year":"2006","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0230","doi-asserted-by":"crossref","first-page":"e2000080","DOI":"10.1371\/journal.pbio.2000080","article-title":"Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation","volume":"15","author":"Riethmueller","year":"2017","journal-title":"PLoS Biol."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119143_bb0235","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.bbamcr.2021.119143_bb0240","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","article-title":"Therapeutic IL-6 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0245","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/0006-291X(92)92272-Y","article-title":"Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor","volume":"189","author":"M\u00fcllberg","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0250","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/eji.1830230226","article-title":"The soluble interleukin-6 receptor is generated by shedding","volume":"23","author":"M\u00fcllberg","year":"1993","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119143_bb0255","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.4049\/jimmunol.155.11.5198","article-title":"A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor","volume":"155","author":"M\u00fcllberg","year":"1995","journal-title":"J. Immunol."},{"issue":"6618","key":"10.1016\/j.bbamcr.2021.119143_bb0260","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"issue":"6618","key":"10.1016\/j.bbamcr.2021.119143_bb0265","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/385733a0","article-title":"Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha","volume":"385","author":"Moss","year":"1997","journal-title":"Nature"},{"issue":"40","key":"10.1016\/j.bbamcr.2021.119143_bb0270","doi-asserted-by":"crossref","first-page":"38829","DOI":"10.1074\/jbc.M210584200","article-title":"Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE)","volume":"278","author":"Matthews","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2021.119143_bb0275","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood-2007-01-067918","article-title":"Apoptosis is a natural stimulus of IL6R shedding and contributes to the pro-inflammatory trans-signaling function of neutrophils","volume":"110","author":"Chalaris","year":"2007","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bbamcr.2021.119143_bb0280","doi-asserted-by":"crossref","first-page":"14804","DOI":"10.1074\/jbc.M111.229393","article-title":"Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding","volume":"286","author":"Garbers","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119143_bb0285","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.4049\/jimmunol.180.11.7102","article-title":"Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells","volume":"180","author":"Briso","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0290","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/art.20727","article-title":"Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells","volume":"52","author":"Franchimont","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119143_bb0295","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1189\/jlb.3A0515-207R","article-title":"ADAM17 controls IL-6 signaling by cleavage of the murine IL-6R\u03b1 from the cell surface of leukocytes during inflammatory responses","volume":"99","author":"Yan","year":"2015","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0300","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1038\/s41598-019-43617-5","article-title":"Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling","volume":"9","author":"Flynn","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0305","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1084\/jem.189.3.599","article-title":"C-reactive protein: a physiological activator of interleukin 6 receptor shedding","volume":"189","author":"Jones","year":"1999","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.bbamcr.2021.119143_bb0310","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.4049\/jimmunol.152.10.4958","article-title":"The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site","volume":"152","author":"M\u00fcllberg","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbamcr.2021.119143_bb0315","doi-asserted-by":"crossref","first-page":"25550","DOI":"10.1038\/srep25550","article-title":"Cleavage site localization differentially controls interleukin-6 receptor proteolysis by ADAM10 and ADAM17","volume":"6","author":"Riethmueller","year":"2016","journal-title":"Sci. Rep."},{"issue":"47","key":"10.1016\/j.bbamcr.2021.119143_bb0320","doi-asserted-by":"crossref","first-page":"14623","DOI":"10.1073\/pnas.1511175112","article-title":"A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation","volume":"112","author":"Goth","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119143_bb0325","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1089\/107999099312957","article-title":"Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation","volume":"19","author":"Bank","year":"1999","journal-title":"J. Interf. Cytokine Res."},{"issue":"7","key":"10.1016\/j.bbamcr.2021.119143_bb0330","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.celrep.2016.01.053","article-title":"Proteolytic cleavage governs interleukin-11 trans-signaling","volume":"14","author":"Lokau","year":"2016","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0335","doi-asserted-by":"crossref","first-page":"21612","DOI":"10.1038\/s41598-020-77884-4","article-title":"Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro","volume":"10","author":"Flynn","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbamcr.2021.119143_bb0340","doi-asserted-by":"crossref","first-page":"44053","DOI":"10.1038\/srep44053","article-title":"Meprin Metalloproteases generate biologically active soluble Interleukin-6 receptor to induce trans-signaling","volume":"7","author":"Arnold","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0345","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1038\/s41598-017-07556-3","article-title":"Quantitative proteomics screen identifies a substrate repertoire of rhomboid protease RHBDL2 in human cells and implicates it in epithelial homeostasis","volume":"7","author":"Johnson","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0350","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002087R","article-title":"Interleukin-11 (IL-11) receptor cleavage by the rhomboid protease RHBDL2 induces IL-11 trans-signaling","volume":"35","author":"Koch","year":"2021","journal-title":"FASEB J."},{"issue":"21","key":"10.1016\/j.bbamcr.2021.119143_bb0355","doi-asserted-by":"crossref","first-page":"14177","DOI":"10.1074\/jbc.R700052200","article-title":"Molecular mechanisms of soluble cytokine receptor generation","volume":"283","author":"Levine","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119143_bb0360","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/j.bbamcr.2016.09.002","article-title":"Stimulated release and functional activity of surface expressed metalloproteinase ADAM17 in exosomes","volume":"1863","author":"Groth","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119143_bb0365","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.4049\/jimmunol.1301019","article-title":"Adrenergic regulation of IgE involves modulation of CD23 and ADAM10 expression on exosomes","volume":"191","author":"Padro","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbamcr.2021.119143_bb0370","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.gene.2018.07.018","article-title":"Horizontal transfer of exosomal CXCR4 promotes murine hepatocarcinoma cell migration, invasion and lymphangiogenesis","volume":"676","author":"Li","year":"2018","journal-title":"Gene"},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119143_bb0375","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3390\/cells9051307","article-title":"Joint reconstituted signaling of the IL-6 receptor via extracellular vesicles","volume":"9","author":"Arnold","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119143_bb0380","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/sj.gene.6364120","article-title":"Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced","volume":"5","author":"Galicia","year":"2004","journal-title":"Genes Immun."},{"issue":"7","key":"10.1016\/j.bbamcr.2021.119143_bb0385","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.gene.6364414","article-title":"A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects","volume":"8","author":"Rafiq","year":"2007","journal-title":"Genes Immun."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119143_bb0390","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1021\/pr401135u","article-title":"LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries","volume":"13","author":"Tucher","year":"2014","journal-title":"J. Proteome Res."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119143_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003444","article-title":"Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases","volume":"9","author":"Ferreira","year":"2013","journal-title":"PLoS Genet."},{"issue":"9822","key":"10.1016\/j.bbamcr.2021.119143_bb0400","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"issue":"9822","key":"10.1016\/j.bbamcr.2021.119143_bb0405","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"issue":"48","key":"10.1016\/j.bbamcr.2021.119143_bb0410","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/eurheartj\/ehs354","article-title":"Interleukin-6 receptor pathways in abdominal aortic aneurysm","volume":"34","author":"Harrison","year":"2013","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0415","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.118.002413","article-title":"Interleukin-6 receptor signaling and abdominal aortic aneurysm growth rates","volume":"12","author":"Paige","year":"2019","journal-title":"Circ. Genom. Precis. Med."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119143_bb0420","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0425","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.gastro.2018.05.022","article-title":"Variation in interleukin 6 receptor gene associates with risk of Crohn\u2019s disease and ulcerative colitis","volume":"155","author":"Parisinos","year":"2018","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bbamcr.2021.119143_bb0430","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1523\/JNEUROSCI.2830-13.2014","article-title":"Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain","volume":"34","author":"Campbell","year":"2014","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0435","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3233\/JAD-160524","article-title":"A common variant of IL-6R is associated with elevated IL-6 pathway activity in Alzheimer\u2019s disease brains","volume":"56","author":"Haddick","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"9839","key":"10.1016\/j.bbamcr.2021.119143_bb0440","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(12)61246-X","article-title":"The interleukin 6 pathway and atherosclerosis","volume":"380","author":"Scheller","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119143_bb0445","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.V82.4.1120.1120","article-title":"Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130","volume":"82","author":"Narazaki","year":"1993","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.bbamcr.2021.119143_bb0450","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0014-5793(93)80507-Q","article-title":"Differential shedding of the two subunits of the interleukin-6 receptor","volume":"332","author":"M\u00fcllberg","year":"1993","journal-title":"FEBS Lett."},{"issue":"31","key":"10.1016\/j.bbamcr.2021.119143_bb0455","doi-asserted-by":"crossref","first-page":"16186","DOI":"10.1074\/jbc.M116.718551","article-title":"Different soluble forms of the Interleukin-6 family signal transducer gp130 fine-tune the blockade of interleukin-6 trans-signaling","volume":"291","author":"Wolf","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2021.119143_bb0460","author":"Bowman Rogers"},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0465","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1172\/JCI7479","article-title":"Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis","volume":"106","author":"Tanaka","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"17","key":"10.1016\/j.bbamcr.2021.119143_bb0470","doi-asserted-by":"crossref","first-page":"10798","DOI":"10.1074\/jbc.273.17.10798","article-title":"Identification and characterization of two distinct truncated forms of gp130 and a soluble form of leukemia inhibitory factor receptor-chain in normal human urine and plasma","volume":"273","author":"Zhang","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"32","key":"10.1016\/j.bbamcr.2021.119143_bb0475","doi-asserted-by":"crossref","first-page":"22140","DOI":"10.1074\/jbc.M114.560938","article-title":"Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10","volume":"289","author":"Sommer","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0480","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0014-5793(97)00750-3","article-title":"Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130","volume":"412","author":"Diamant","year":"1997","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119143_bb0485","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1095\/biolreprod53.4.974","article-title":"Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryos","volume":"53","author":"Sharkey","year":"1995","journal-title":"Biol. Reprod."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119143_bb0490","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.bbrc.2016.01.127","article-title":"A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide-bridge resulting from alternative mRNA splicing","volume":"470","author":"Wolf","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0495","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/BJ20060544","article-title":"Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cycling","volume":"398","author":"Lin","year":"2006","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0500","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119143_bb0505","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.metabol.2014.02.005","article-title":"Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels","volume":"63","author":"Wonnerth","year":"2014","journal-title":"Metabolism"},{"issue":"1\u20133","key":"10.1016\/j.bbamcr.2021.119143_bb0510","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.regpep.2007.09.031","article-title":"A non-conservative polymorphism in the IL-6 signal transducer (IL6ST)\/gp130 is associated with myocardial infarction in a hypertensive population","volume":"146","author":"Benrick","year":"2008","journal-title":"Regul. Pept."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2020.151964","article-title":"Increased levels of the soluble oncostatin M receptor (sOSMR) and glycoprotein 130 (sgp130) in systemic sclerosis patients and associations with clinical parameters","volume":"225","author":"de Almeida","year":"2020","journal-title":"Immunobiology"},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0520","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1536\/ihj.53.182","article-title":"Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure","volume":"53","author":"Kinugawa","year":"2012","journal-title":"Int. Heart J."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0525","first-page":"101","article-title":"Plasma levels of soluble glycoprotein 130 in acute myocardial infarction","volume":"50","author":"Ichiki","year":"2007","journal-title":"J. Cardiol."},{"issue":"7","key":"10.1016\/j.bbamcr.2021.119143_bb0530","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00384-018-3069-8","article-title":"Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases","volume":"33","author":"Nikolaus","year":"2018","journal-title":"Int. J. Color. Dis."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0535","doi-asserted-by":"crossref","first-page":"E411","DOI":"10.1152\/ajpendo.00166.2019","article-title":"The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes","volume":"317","author":"Aparicio-Siegmund","year":"2019","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119143_bb0540","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/1354750X.2018.1458151","article-title":"Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis","volume":"23","author":"Korotaeva","year":"2018","journal-title":"Biomarkers"},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0545","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/cvr\/cvy191","article-title":"Interleukin 6 trans-signalling and risk of future cardiovascular events","volume":"115","author":"Ziegler","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"9","key":"10.1016\/j.bbamcr.2021.119143_bb0550","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119143_bb0555","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0560","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/S2665-9913(20)30416-1","article-title":"Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19","volume":"3","author":"Garbers","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.bbamcr.2021.119143_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100340","article-title":"Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm","volume":"22","author":"Garbers","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0570","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.immuni.2020.12.001","article-title":"The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells","volume":"54","author":"Yousif","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0575","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.smim.2014.01.009","article-title":"A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy","volume":"26","author":"Tanaka","year":"2014","journal-title":"Semin. Immunol."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119143_bb0580","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/1744666X.2017.1295850","article-title":"The role and therapeutic targeting of IL-6 in rheumatoid arthritis","volume":"13","author":"Narazaki","year":"2017","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119143_bb0585","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119143_bb0590","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"10229","key":"10.1016\/j.bbamcr.2021.119143_bb0595","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.bbamcr.2021.119143_bb0600","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0605","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jcpt.13303","article-title":"Tocilizumab use in patients with moderate to severe COVID-19: a retrospective cohort study","volume":"46","author":"Chilimuri","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0610","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/joim.13162","article-title":"Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study","volume":"289","author":"Eimer","year":"2021","journal-title":"J. Intern. Med."},{"issue":"8","key":"10.1016\/j.bbamcr.2021.119143_bb0615","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.bbamcr.2021.119143_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100418","article-title":"Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study","volume":"24","author":"Kewan","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bbamcr.2021.119143_bb0625","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","article-title":"Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study","volume":"76","author":"Campochiaro","year":"2020","journal-title":"Eur. J. Intern. Med."},{"issue":"10285","key":"10.1016\/j.bbamcr.2021.119143_bb0630","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Group","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119143_bb0635","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/rheumatology\/ker223","article-title":"Risk of infections in rheumatoid arthritis patients treated with tocilizumab","volume":"51","author":"Lang","year":"2012","journal-title":"Rheumatology"},{"issue":"6469","key":"10.1016\/j.bbamcr.2021.119143_bb0640","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/368339a0","article-title":"Impaired immune and acute-phase responses in interleukin-6-deficient mice","volume":"368","author":"Kopf","year":"1994","journal-title":"Nature"},{"issue":"45","key":"10.1016\/j.bbamcr.2021.119143_bb0645","doi-asserted-by":"crossref","first-page":"26943","DOI":"10.1074\/jbc.M115.682138","article-title":"Novel insights into interleukin 6 (IL-6) cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex","volume":"290","author":"Lacroix","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119143_bb0650","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232612","article-title":"Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells","volume":"15","author":"Lokau","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bbamcr.2021.119143_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154281","article-title":"Letter to the editor: non-specific effects resulting from use of tocilizumab in mice","volume":"109","author":"Lokau","year":"2020","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0660","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","article-title":"Soluble gp130 is the natural inhibitor of soluble IL-6R transsignaling responses","volume":"268","author":"Jostock","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"50","key":"10.1016\/j.bbamcr.2021.119143_bb0665","doi-asserted-by":"crossref","first-page":"42959","DOI":"10.1074\/jbc.M111.295758","article-title":"Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor","volume":"286","author":"Garbers","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.bbamcr.2021.119143_bb0670","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","article-title":"The balance of interleukin (IL)-6, IL-6.soluble IL-6 receptor (sIL-6R), and IL-6.sIL-6R.sgp130 complexes allows simultaneous classic and trans-signaling","volume":"293","author":"Baran","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119143_bb0675","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4049\/jimmunol.182.1.613","article-title":"Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis","volume":"182","author":"Nowell","year":"2009","journal-title":"J. Immunol. (Baltimore, Md. 1950)"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0680","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4049\/jimmunol.1201044","article-title":"IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling","volume":"190","author":"Hoge","year":"2013","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119143_bb0685","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/CCM.0b013e318211ff56","article-title":"Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model","volume":"39","author":"Barkhausen","year":"2011","journal-title":"Crit. Care Med."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119143_bb0690","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jacbts.2021.01.013","article-title":"Selective interleukin-6 trans-signaling blockade is more effective than panantagonism in reperfused myocardial infarction","volume":"6","author":"George","year":"2021","journal-title":"JACC Basic Transl. Sci."},{"issue":"Supplement_1","key":"10.1016\/j.bbamcr.2021.119143_bb0695","doi-asserted-by":"crossref","first-page":"S041","DOI":"10.1093\/ecco-jcc\/jjab073.040","article-title":"DOP01 efficacy and safety of the IL-6 trans-signalling inhibitor olamkicept: a phase 2 randomized, placebo-controlled trial in moderately to severely active ulcerative colitis","volume":"15","author":"Chen","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytox.2020.100029","article-title":"SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the \u2018culprit lesion\u2019 of ARDS onset? What is there besides Tocilizumab? SGP130Fc","volume":"2","author":"Magro","year":"2020","journal-title":"Cytokine X"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119143_bb0705","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbrc.2004.11.098","article-title":"No inhibition of IL-27 signaling by soluble gp130","volume":"326","author":"Scheller","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0710","first-page":"104","article-title":"Colonic mucosal interleukin-6 in inflammatory bowel disease","volume":"50","author":"Mitsuyama","year":"1991","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119143_bb0715","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119143_bb0720","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.20171696","article-title":"ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling","volume":"215","author":"Schmidt","year":"2018","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119143_bb0725","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.0801217","article-title":"Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6\/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model","volume":"184","author":"Matsumoto","year":"2010","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119143_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.04.002","article-title":"The metalloprotease ADAM17 in inflammation and cancer","volume":"215","author":"D\u00fcsterh\u00f6ft","year":"2019","journal-title":"Pathol. Res. Pract."},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119143_bb0735","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111736","article-title":"ADAM17 activity and IL-6 trans-signaling in inflammation and cancer","volume":"11","author":"Schumacher","year":"2019","journal-title":"Cancers (Basel)"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016748892100197X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016748892100197X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:35:20Z","timestamp":1778632520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016748892100197X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S016748892100197X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2021.119143","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2021.119143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119143"}}